Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment
- PMID: 12368163
Relationship between international normalized ratio values, vitamin K-dependent clotting factor levels and in vivo prothrombin activation during the early and steady phases of oral anticoagulant treatment
Abstract
Background and objectives: In vitro studies have shown that the rate of prothrombin activation is linearly related to the concentration of factor II (FII) in the assay system, suggesting a key role of prothrombin levels in the expression of the antithrombotic activity of oral anticoagulant treatment (OAT). We investigated the in vivo relationship between prothrombin activation and vitamin K-dependent clotting factor levels during the early and steady phases of OAT in patients and in healthy volunteers.
Design and methods: The changes in international normalizezd ratio (INR) and in the plasma levels of FVII, FX, FII, protein C (PC) and prothrombin fragment 1.2 (F1+2) induced by OAT were monitored over 9 days in 10 patients not on heparin starting warfarin after heart valve replacement (HVR) and in 9 healthy volunteers submitted to an 8-day course of warfarin treatment. FII and F1+2 plasma levels were also measured in 100 patients on stable oral anticoagulant treatment with INRs ranging from 1.2 to 6.84.
Results: Because HVR patients had subnormal FVII, FX and FII levels after surgery, INR values > 2.0 were attained already 24 hours after the first warfarin dose. In healthy volunteers, INR values greater than 2.0 were first observed after 72 hours. Nadir levels of FVII, PC, FX and FII were reached between 40 and 88 hours in HVR patients and between 72 and 192 hours in healthy volunteers. The FII apparent half-disappearance time (t/2) was 99 hours in HVR patients and 115 hours in healthy volunteers (p = ns). In HVR patients there was no normalization of initially elevated F1+2 levels until day 7 with an apparent t/2 of 132 hours. In healthy volunteers, a decrease to subnormal F1+2 levels was observed by day 8 of treatment (apparent t/2 = 107 hours). In both HVR patients and healthy volunteers, FII and PC levels were independent predictors of the changes in F1+2 levels (p = 0.0001). In patients on stable OAT, only FII levels were independent predictors of the variation in F1+2 levels (p = 0.0001).
Interpretation and conclusions: During the early phase of oral anticoagulant treatment in vivo prothrombin activation is a function of the balance between FII and PC levels and is not significantly prevented until nadir levels of FII are obtained. This provides an explanation for the requirement of overlapping heparin and oral anticoagulant treatment for at least 48 hours after the achievement of therapeutic INR values in patients with thromboembolic diseases. In addition, in vivo prothrombin activation is a function of FII levels rather than INR values also in patients on stable oral anticoagulant treatment.
Similar articles
-
Discrepant sensitivity of thromboplastin reagents to clotting factor levels explored by the prothrombin time in patients on stable oral anticoagulant treatment: impact on the international normalized ratio system.Haematologica. 2002 Dec;87(12):1265-73. Haematologica. 2002. PMID: 12495900
-
Warfarin or acenocoumarol: which is better in the management of oral anticoagulants?Thromb Haemost. 1998 Dec;80(6):899-902. Thromb Haemost. 1998. PMID: 9869157 Clinical Trial.
-
Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment.Thromb Haemost. 1998 Mar;79(3):571-3. Thromb Haemost. 1998. PMID: 9531043
-
Pharmacokinetic and pharmacodynamic properties of oral anticoagulants, especially phenprocoumon.Semin Thromb Hemost. 1999;25(1):5-11. doi: 10.1055/s-2007-996417. Semin Thromb Hemost. 1999. PMID: 10327214 Review.
-
Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations.Clin Pharmacokinet. 1996 Apr;30(4):300-13. doi: 10.2165/00003088-199630040-00003. Clin Pharmacokinet. 1996. PMID: 8983860 Review.
Cited by
-
The impact of R353Q genetic polymorphism in coagulation factor VII on the initial anticoagulant effect exerted by warfarin.Eur J Clin Pharmacol. 2019 Mar;75(3):343-350. doi: 10.1007/s00228-018-2594-2. Epub 2018 Nov 9. Eur J Clin Pharmacol. 2019. PMID: 30411147
-
[Anticoagulation. Modern concepts].Herz. 2012 Jun;37(4):407-13; quiz 414-5. doi: 10.1007/s00059-012-3622-0. Herz. 2012. PMID: 22592953 German.
-
Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients.Thromb J. 2003 Nov 30;1(1):7. doi: 10.1186/1477-9560-1-7. Thromb J. 2003. PMID: 14969588 Free PMC article.
-
The need for an adapted initiation nomogram during Fiix prothrombin time monitoring of warfarin.J Thromb Thrombolysis. 2019 Nov;48(4):685-689. doi: 10.1007/s11239-019-01928-4. J Thromb Thrombolysis. 2019. PMID: 31401717
-
A factor VII-based method for the prediction of anticoagulant response to warfarin.Sci Rep. 2018 Aug 13;8(1):12041. doi: 10.1038/s41598-018-30516-4. Sci Rep. 2018. PMID: 30104739 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous